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COMPARISON OF PATIENT OUTCOME FOR AORTIC VALVE 
REPLACEMENT VERSES TRANSCATHETER AORTIC VALVE 
REPLACEMENT 
JOSHUA GOLDBERG 
ABSTRACT 
 Aortic stenosis or narrowing of the aortic valve is the most common cause for 
surgical valvular replacement in the United States.  The disease of aortic stenosis has a 
long asymptomatic latency period followed by a quickly progressing symptomatic phase.  
Symptoms of the disease include dyspnea, syncope, angina, and heart failure.  The 
disease affects mostly the elderly and, as the United States population ages, and life 
expectancy increases, there is an increased prevalence of the disease.  The main cause of 
aortic stenosis is calcification of the leaflets of the aortic valve.  There are currently no 
pharmaceutical interventions to combat or slow the processes of the disease.  The only 
treatment for the disease is the surgical replacement of the aortic valve.  The original 
aortic valve replacement (AVR) was done in 1952, after that time this was the only 
surgical intervention until 2002 with the advent of transcatheter aortic valve replacement 
(TAVR).  TAVR has since been approved by the Food and Drug Administration (FDA) 
for use in patients who are not candidates for AVR or who are at high risk for AVR.  
 The initial studies of TAVR showed an elevated risk of stroke in those 
undergoing surgery but it provided similar relief of symptoms, and similar patient 
mortality at one and two year follow up.  With the increased risk of stroke there was 
evaluation of cause and mechanism of the cerebral events.  After concluding that the 
	  	   vii 
strokes were due to emboli released during mechanical movement during surgery, new 
technologies have begun to be developed to combat the stroke risk.  One device that is 
used is a deflection device that ensures that an embolus does not have access to cerebral 
circulation.  
 Through the study of current literature it can be concluded that the patient long-
term outcomes are much improved in TAVR verse AVR for the subgroup of the 
population who are not candidates for surgery.  There are comparable patient outcomes 
for those who are at a high risk for surgery, but the risk for stroke with TAVR doubled 
compared to AVR, which continues to be investigated.  TAVR carries the benefit of a 
less invasive surgery, shorter hospital stays and reported increased quality of life one-
year post operation.  This study demonstrates that there is still a need for further 
development of technology, surgical technique and long term patient follow up to ensure 
high quality outcome for those undergoing TAVR.  
  
	  	   viii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
DEDICATION ................................................................................................................... iv 
ACKNOWLEDGMENTS .................................................................................................. v 
ABSTRACT ....................................................................................................................... vi 
TABLE OF CONTENTS ................................................................................................. viii 
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES ............................................................................................................ x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
INTRODUCTION .............................................................................................................. 1 
PUBLISHED STUDIES ................................................................................................... 33 
DISCUSSION ................................................................................................................... 51 
REFERENCES ................................................................................................................. 59 
CURRICULUM VITAE ................................................................................................... 63 
 
  
	  	   ix 
LIST OF TABLES 
 
 
Table Title Page 
1 Methods for diagnosing aortic stenosis 21 
2 Options of surgery for aortic stenosis 25 
3  Patient clinical results TAVR verses standard therapy 34 
4 Patient clinical results in transcatheter aortic valve 
implantation vs aortic valve replacement 
38 
5 Quality of Life Scales 49 
   
 
  
	  	   x 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Cardiac blood flow 3 
2 Cellular layers of aortic valve 5 
3 Calcification mechanisms 8 
4 Age distribution of aortic stenosis 12 
5 Clinic course of aortic valve stenosis 16 
6 Pharmaceutical strategies for combating aortic stenosis 23 
7 New surgical development 29 
8 Current valvular choices 30 
9 Cause of death curves and outcome period 35 
10 Comparing AVR to TAVR patient outcomes 41 
11 The role of aortic regurgitation on patient mortality 43 
   
   
   
   
  
	  	   xi 
LIST OF ABBREVIATIONS 
 
AVR ............................................................................................ Aortic Valve Replacement 
FDA ..................................................................................... Food and Drug Administration 
TAVR ................................................................... Transcatheter Aortic Valve Replacement 
 
 
 
	  1 
INTRODUCTION 
 Aortic stenosis, a severe heart disease that once symptomatic, quickly leads to 
death if left untreated and is the most common cause for cardiac valve replacement in 
both Europe and North America (Cary & Pearce, 2013; Lester & Abbas, 2014).  Aortic 
stenosis causes an obstruction of the left ventricular cardiac blood flow due to a reduction 
in area of the aortic valve opening.  The symptoms include difficulty breathing (dyspnea), 
heart failure, chest pain (angina), and temporary loss of consciousness (syncope).  
Pharmaceutical intervention for symptomatic patients is very limited, and the gold 
standard of treatment is surgical aortic valve replacement (AVR).  In recent years, the 
development of transcatheter aortic valve replacement (TAVR) was developed as an 
alternative to surgery for those who were at high risk for the standard surgical 
intervention (Carabello, 2013).  Each technique has its own benefits, risk factors, and 
patient outcomes.  Debate continues as to which method should be used for each 
individual patient case. This thesis will be comparing the specific patient outcomes of 
these two surgical techniques, providing insight into future development of the treatment 
of aortic stenosis.  
 The human heart’s main function is to receive deoxygenated blood from the 
venous side of the circulatory system, provide a pumping force to move the blood to the 
pulmonary system for oxygenation and then out of the heart back to the systemic 
circulation to satisfy tissue needs.  The deoxygenated blood from venous circulation first 
enters the right atrium via the superior and inferior vena cava.  The blood is then moved 
from the higher-pressure chamber of the right atrium to the lower-pressure chamber of 
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the right ventricle passing through the bicuspid valve.  Each valve of the heart is designed 
to allow only one-way passage of blood in order to ensure a constant unidirectional flow 
of the circulation.  Once the blood has reached the right ventricle, during systole or 
contraction, the blood is pumped through the pulmonary valve to the pulmonary system 
where oxygenation of the blood occurs.  The blood flows from the pulmonary circulation 
to the left atrium where it then moves through the mitral valve into the left ventricle.  The 
movement of blood from the left atrium to the left ventricle is carried out again by 
pressure differences of the two chambers, where the atrium initially has a higher pressure 
than the ventricle.  Again during systole, the blood is pumped out of the left ventricle 
through the aortic valve and into the aorta where it is now free to enter the systemic 
circulation and provide oxygen to the tissues.  Both the right and left atrium contract in 
unison during diastole, and the two ventricles contract simultaneously during systole.  
The coordinated cardiac contraction, chamber system, and valves allow for unidirectional 
flow of circulation.  Any disturbance to this system can create severe symptoms or death 
(Morton, 2011).  
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Figure 1: Cardiac blood flow-The deoxygenated blood enters the heart through the 
inferior and superior vena cava.  Blood enters from the right atrium (RA) to the right 
ventricle (RV), and to the pulmonary circulation for oxygenation.  Oxygenated blood 
now enters the left atrium, to the left ventricle and finally out the aorta to the systemic 
circulation.  Taken from Morton, 2011.   
 
Stenosis in general is narrowing of an organ structure; therefore, aortic stenosis is 
a narrowing of the opening to the aortic valve.  When aortic stenosis occurs it causes 
obstruction of blood flow from the left ventricle through the aortic valve out into the 
aorta.  This obstruction increases the work load of the cardiac muscle and leads to the 
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symptoms mentioned above as the cardiac system attempts to compensate for this change 
(Cary & Pearce, 2013).  First defined by Dr. Lazare Rivière in 1663, aortic stenosis was 
described during autopsy on a patient who was found to have ventricular enlargement and 
calcified obstruction to the left ventricular outflow through the aortic valve.  The original 
belief was that the calcification was caused by an inflammatory response to a bacterial 
infection, known as endocarditis.  In 1846, there was a challenge to this theory attributing 
the calcification to valvular degeneration (Leopold, 2012; Mylonakis & Calderwood, 
2001). Since that time, both theories have been reevaluated and the current conclusion on 
the cause of calcification is that calcification is not a passive process, but is one that is 
due to active cellular infiltration of immune cells or other altered cells entering the 
normal tissue.  During a normal immune response, immune cells such as macrophages or 
lymphocytes will enter or infiltrate the injured tissue in order to carry out their immune 
function.  In aortic stenosis, this same immune cell infiltration mechanism can occur after 
injury to the valve leading to immune cell accumulation in the valvular tissue.  The cause 
of aortic stenosis came only with the development and research of the cellular 
composition of the aortic valve itself and the cells that were present once aortic 
calcification had occurred (Alexopoulos et al.,  2012).  
A clear understanding of the specific anatomy and makeup of the aortic valve is 
necessary in order to have a better understanding of aortic stenosis and how the disease 
actively progresses.  The aortic valve is located between the left atrium and the aorta, and 
consists of three avascular leaflets that meet in the center to form the valve.  The leaflets 
ensure a one-way passage of blood from the left ventricle to the aorta.  There are three 
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layers of cell types in the aortic valve providing the site for possible ossification and 
stenosis or narrowing of the valve opening.  The cell type that faces the aorta is the 
fibrosa layer that consists of collagen fibers.  The ventricularis layer is made of mostly 
elastic fibers and faces the ventricle aspect.  The spongiosa layer is in the middle of three 
layers consisting of glycosaminoglycans and proteoglycans in order to minimize friction 
and stress between the two outer layers.  The three layers respectively provide strength, 
elasticity in times of stretch, and cushion (Cary & Pearce, 2013).  Cellular response to 
injury within these different layers causes cells to alter their function, which leads to 
calcification causing valvular hardening, and ultimately leads to aortic stenosis with its 
subsequent cardiac symptoms.  
 
 
 
 
 
  
 
Figure 2: Cellular layers of aortic valve- The normal aortic valve consists of three 
layers, fibrosa, ventricularis and spongiosa.  They provide strength, elasticity, and 
cushion respectively.  Taken from Dweck et al., 2012.  
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 The disease of aortic stenosis begins with aortic sclerosis or tissue hardening.  
This sclerosis gradually worsens to create a stenotic aortic valve or valve with less area 
for blood to pass through, gradually leading to partial blockage of the blood flow from 
the left ventricle to the aorta.  Aortic sclerosis itself is present in 25% of those 65 years 
old, creating a decently large population that is at risk for developing aortic stenosis 
(Alexopoulos et al., 2012).  However, this processes of valve hardening takes many 
years, with only 10% of patients progressing from having aortic sclerosis to 
hemodynamically compromised aortic stenosis with changes in the normal blood flow 
that requires intervention (Cary & Pearce, 2013).   
The majority of cases of aortic stenosis are due to calcification of the aortic valve 
leaflets.  The leaflets of the valve begin to accumulate calcium deposits, eventually 
making them larger and decreasing the aortic valve opening or stenosis.  Aortic stenosis 
has been linked to similar pathways of disease progression of atherosclerosis or lipid 
deposition in arteries and also to bone deposition with the presence of osteoblastic cells, 
whose cellular function is to lay down new-formed bone.  During either process there is 
cellular deposit on the leaflet.  In the atherosclerotic pathway, lipid deposition creates 
increased area that calcium can be further deposited upon.  The calcification of the aortic 
valve causes over 80% of the cases of aortic stenosis and is termed calcific aortic valve 
disease (Rayner et al., 2014).  Both calcified aortic stenosis and atherosclerosis have 
similar risk factors and cell infiltration processes.  The risk factors include older age, 
male gender, hypertension, history of smoking, and elevated lipoprotein and low-density 
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lipoprotein levels.  Genetics can also affect the onset of aortic stenosis.  There is a direct 
relationship of genetic factors and the ossification load on the aortic valve that leads to 
stenosis (Alexopoulos et al., 2012).  
 The similarities between the cellular mechanisms of aortic stenosis and 
atherosclerosis are demonstrated by the observation of the similar cell types that infiltrate 
the tissue during either process.  Atherosclerosis is a process that is initiated with cellular 
injury followed by inflammatory response with cellular infiltration, which in turn leads to 
eventual lipid deposition.  During normal aortic tissue function there are very few 
inflammatory cells, macrophages or leukocytes, whereas during atherosclerosis and aortic 
stenosis there are very elevated levels of both these cell types, indicating the integration 
of the inflammatory response for both of the processes (Alexopoulos et al., 2012).   
Originally, aortic stenosis was thought to be a passive process where calcification 
of the valve occurred over time, but it is now known that the process is active and due to 
cellular accumulation within the valvular tissue.  
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Figure 3: Calcification mechanisms-This diagram shows the different cellular pathways 
that can occur to lead to calcification of the aortic valve.  Taken from Leopold, 2012.  
 
The aortic valve cell types display aspects of functional plasticity and have the ability to 
change their utility due to certain stresses.  This change in phenotype is the basis for the 
cells’ novel functional expression causing aortic stenosis, as the cells either now 
accumulate or actively deposit bone structure, or calcification. 
 Several mechanisms can cause this calcification to occur:  cellular injury, 
improperly functioning regulatory cells or endothelial cells, or the presence of bone 
marrow derived cells.   
Cellular injury can come from various factors including direct endothelial injury, 
lipid accumulation, or inflammatory cell infiltration into the endothelial lining.  The 
initial injury or cellular accumulation (lipid, or inflammatory) causes a remodeling of the 
valvular interstitial cells which ultimately leads to the cells transforming their ability to 
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produce osteoid.  This newly deposited osteoid, eventually causes calcification of the 
aortic valve as the processes occurs over time (Alexopoulos et al., 2012).  The cellular 
transformation can cause deposition of lamellar bone with bone marrow, chondrocytes, 
cartilage, and endochondral calcification, which create calcific nodules.  The majority of 
these calcific nodules occurs on the fibrosa layer of the valve, and often extends in to the 
aortic side of the valve.  This placement of the aortic calcification ultimately causes the 
utility of the valve to function improperly, creating greater resistance of blood flow from 
the left ventricle to aorta, ultimately leading to aortic stenosis.   
 In addition to cellular injury and the subsequent transformation of cellular 
function that can lead to calcific nodules, improperly functioning regulatory cells can also 
cause aortic calcification.  In normal functioning tissue, these cells regulate activation or 
inhibition of gene transcription factors leading to cellular replication, function 
transformation, or cellular activation.  Poorly functioning regulatory cells can lead to an 
imbalance, with more cell deposition than inhibition, which ultimately leads to net 
calcification (Leopold, 2012).  
 In addition to the mechanisms of cellular injury or improperly functioning 
regulatory cells, a third mechanism of calcification involves the individual endothelial 
cells of the valve undergoing transition, requiring no infiltration of other cell types as was 
seen with the inflammatory response mechanism.  This cellular transition ultimately leads 
to the same outcome as the inflammatory response, with the valve becoming calcified and 
hardened with a decreased area for the blood to flow through.  In this transition, the 
individual endothelial cell differentiates into an osteoblastic like cell with a new ability to 
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deposit bone material.  This change in cellular function is carried out through an 
endothelial-to-mesenchymal-transition where the cells lose their endothelial 
characteristics along with their adhesion properties.  The endothelial-to-mesenchymal 
transition is believed to be caused by activation of cellular growth factors, transcription 
factors and signaling pathways, although the activation of these cellular pathways is still 
under investigation.  The loss of adhesion that occurs during the transition allows the 
transformed cells to act as mesenchymal or myofibroblast cells and infiltrate other areas 
contributing to the fibrosis or hardening of the valve (Leopold, 2012).  
 Besides the cellular transitions described, a fourth factor that can contribute to 
aortic valve stenosis is the presence of vascularization to the valve.  The healthy human 
aortic valve is avascular with no direct blood vessels, but during incidence of 
calcification the tissue surrounding the areas of inflammatory cell infiltration becomes 
vascularized.  This occurs near the calcified nodules and beneath the border of the leaflet 
developing a direct blood supply to the tissue.  The new vascularization now allows for a 
more rapid movement of additional inflammatory cells and other cellular signaling 
molecules that will leads to calcification (Leopold, 2012).  
Each of these four different causes of active calcification and eventual narrowing 
of the heart’s ventricles (aortic stenosis) take a long time to develop.  These processes are 
also generally asymptomatic until the calcification and subsequent narrowing of the 
aortic valves are significant enough to cause symptoms.  As aortic stenosis worsens, it 
puts a greater strain on the heart’s overall functioning.  The cardiac functional demand is 
increased as the disease progresses, requiring greater force to move blood from the 
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ventricle to the aorta.  This decrease in the cardiac function can lead to symptoms of 
syncope, dyspnea, angina, and ultimately heart failure.  By the time the patient is 
symptomatic, the cardiac function is already highly compromised and the prognosis is 
poor.  
Due to the fact that aortic stenosis requires such a long time period to develop, up 
to twenty-five years, the elderly are often at the highest risk for disease.  Due to 
compounding population factors, the disease burden of aortic stenosis is increasing in the 
United States ( Figure 4).  Aortic stenosis is most prevalent in those above the age of 65.  
As the elderly population in the United States begins to grow, and life expectancy 
continues to increase, the disease prevalence will continue to rise (Cary & Pearce, 2013).   
 This increasing disease burden is compounded by the fact that as of yet, there is 
no pharmaceutical preventative action that can be taken to combat the disease (Cary & 
Pearce, 2013).  In the United States, there has been an increase in age-adjusted mortality 
secondary to aortic valve disease by 1.6% per year between 1978 and 2009 (Rayner et al., 
2014).  This increase in the disease prevalence and burden to the medical system shows 
the great need for more options for medical intervention, once patients are diagnosed.  
Preventive options currently exist, but must be initiated more effectively at earlier stages 
in order to reduce the long-term disease prevalence and burden of aortic stenosis.  In 
2012, aortic stenosis led to 28,000 deaths and 48,000 hospitalizations in the United States 
alone.  Aortic stenosis is the most common valve pathology and accounts for 43% of 
patients who present with valvular disease (Leopold, 2012).  The disease is present in 2-
7% of the population that is greater than 65 years old (Alexopoulos et al., 2012). 
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Figure 4: Age distribution of aortic stenosis-The diagram above demonstrates the 
increase of aortic stenosis as the population ages.  Taken from Nkomo et al., 2006.  
   
 Rheumatic fever and congenital defects are two other causes of aortic stenosis 
exist in United States populations that have a relatively minor impact on the population 
age groups most affected by the disease.  Medical interventions for both of these causes, 
once the disease has progressed to symptomatic aortic stenosis, are the same as those 
with calcific aortic valve disease.   
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 Rheumatic fever has the potential to lead to aortic stenosis and is caused by 
untreated pharyngeal infection.  Rheumatic fever can lead to aortic stenosis in younger as 
well as older populations.  Due to an easy treatment regimen of penicillin for 
streptococcal infection among children and adults as prevention for rheumatic fever, there 
are few cases of aortic stenosis caused by rheumatic fever in developed nations.  This 
decrease in rheumatic fever cases has led to a shift in the age group of those who suffer 
with aortic stenosis to an older age population (Cary & Pearce, 2013).   
 The second mechanism for development of aortic stenosis is due to a congenital 
defect, occurring in 1% to 2% of the population, that causes an individual to have an 
aortic valve with two leaflets instead of three.  There is no preventative measure for this 
congenital defect.  The increased stress that these two leaflets must sustain causes on 
average a two-decade earlier onset of aortic stenosis.  The cellular mechanism of stress 
and injury causing aortic stenosis for these two leaflet valves is consistent with the three 
leaflet valves described earlier (Cary & Pearce, 2013).   
 Limited options exist to prevent aortic stenosis.  The disease has two stages:  a 
long latent asymptomatic period followed by a fast progressing symptomatic phase that 
requires surgical intervention for a cure.  There are currently no pharmaceutical 
interventions that are reliable at preventing or slowing the progression of the calcification 
of the aortic valve during its asymptomatic or symptomatic phase (Leopold, 2012). 
However, some behavior changes can be effective in preventing aortic stenosis.  Due to 
the common association with atherosclerosis and aortic valve calcification, preventative 
measures that are used for atherosclerosis can be applied to prevention of calcific aortic 
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stenosis.  For example, avoiding smoking, lowering one’s low-density lipoprotein levels, 
and lowering one’s blood pressure can assist in the prevention of aortic stenosis 
(Alexopoulos et al., 2012).   
 For patients who have asymptomatic aortic stenosis, it is normally not advised to 
provide surgery due to the low risk of sudden death caused by aortic stenosis, compared 
to the slightly higher risk factor that one faces during surgery.  For those who have 
asymptomatic aortic stenosis, their sudden death rate is 0.5%-1% per year, while the risk 
of death during AVR surgery is less than 2.5% for those over thirty-five years old 
(Carabello, 2013).  During surgery patients are at risk of thromboembolism, endocarditis, 
valve failure, bleeding and death.  Consequently, this differential risk has led to the 
general practice to not operate on patients before they become symptomatic (Lester & 
Abbas, 2014).   
 In general practice, asymptomatic patients are not operated on during this period 
of disease progression.  However, there is a subgroup of asymptomatic patients who are 
at higher risk of sudden death who will often be operated on, as their risk of surgical 
death is lower than the risk of sudden death.  Those with transaortic jet velocities >4.0 
m/s, indicating highly decreased area of the valve, those with severe left ventricular 
hypertrophy which indicates a greater work load on the cardiac muscle, those with 
extensive valve calcification, and those with abnormal exercise test results are all at an 
elevated risk of sudden death.  With an indication of more than one of the above risk 
factors, decisions to operate in the asymptomatic phase are often taken to lower the risk 
of sudden death (Carabello, 2013; Dweck et al., 2012).  
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 Due to the long latency period, many patients do not self-report their symptoms.  
The progression of hemodynamic status change, or change in the blood flow, is very 
slow.  There is no abrupt change in status that would lead to symptoms that patients 
would notice easily.  Instead, difficulty in breathing worsens or slow progressive decrease 
in exercise tolerance occurs that the patient may not notice (Cary & Pearce, 2013).  
Detection of calcific aortic valve disease, therefore, commonly occurs either by the 
observation of a systolic murmur, evaluation of new onset atrial fibrillation or during a 
cardiac catheterization for a common comorbidity, symptomatic coronary artery disease, 
due to the association of stenosis with atherosclerosis.  
 Once the disease has become symptomatic, it progresses very quickly with a high 
risk of death of those affected.  The classic symptoms of aortic stenosis are angina, 
exertional syncope, or congestive heart failure.  Those who have developed angina 
pectoralis from aortic stenosis have a 50% mortality rate within five years of symptom 
onset without the use of valve replacement (Lester & Abbas, 2014).   
As shown in the figure below, the latent period is followed by a rapid symptomatic 
decline that is followed by death without surgical intervention.  
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Figure 5: Clinical course of aortic valve stenosis-The disease is characterized by a long 
asymptomatic latent period followed by a rapid progressing symptomatic phase.  Taken 
from Ross & Braunwald, 1968.  
 
The classic symptoms of presentation for symptomatic calcific aortic valve 
disease are angina, syncope and heart failure with dyspnea.  In those that are affected by 
aortic stenosis, about 35% of them present with angina as their initial symptom.  Angina, 
or chest pain, is due to the myocardial tissue not receiving enough oxygenated blood.  
This lack of oxygenated blood is caused by decreased blood outflow due to obstructions 
caused by aortic stenosis, compounded by the need for more oxygenated blood by the 
hypertrophied left ventricle, due to the increased tissue mass (Carabello, 2013).  This is 
further compounded by the fact that as the aortic stenosis severity worsens, the increase 
in wall thickness and hypertrophy is insufficient to compensate for the rising pressures 
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requirements to eject blood through the stenotic valve.  This results in a higher wall stress 
and a drop in ventricular function, ultimately leading to decreased cardiac output causing 
decreased blood to the myocardium and angina.  Left ventricular hypertrophy is the most 
common physical finding for those suffering from calcific aortic valve disease (Lester & 
Abbas, 2014).    
 Syncope is a temporary loss of consciousness, most often due to brief disturbance 
in cerebral blood flow.  It is still debated as the cause of hypotension associated with 
aortic stenosis, but it has been established that this hypotension is what causes syncope in 
the patient group.  The syncope is most often associated with exercise due to the 
physiological changes that occurring during activity (Carabello, 2013). As the body 
begins to exercise, the normal response is to have peripheral vasodilation compensated by 
increased cardiac output, ultimately leading to increased blood pressure and increased 
blood flow to the tissues.  In a calcific aortic valve diseased patient, the normal response 
of vasodilation has no ability to be compensated for with increased cardiac output due to 
a diseased heart (Cary & Pearce, 2013).  The increased resistance in the stenotic valve, or 
the hypertrophied left ventricle, leads to a situation where the heart cannot increase its 
cardiac output to the levels needed.  The vasodilation without compensative effects 
causes a drop in blood pressure and therefore syncope (Carabello, 2013).  
 The cause of dyspnea or shortness of breath associated with calcific aortic valve 
disease is still debated, but most likely is attributed to the systolic or diastolic heart 
failure that often accompanies aortic stenosis (Carabello, 2013). The symptom with the 
worst outcome for aortic disease is heart failure, resulting in death 11 months after 
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symptom onset, compared to 23 months in those with severe aortic stenosis who do not 
develop heart failure (Rayner et al., 2014).   
There are two types of heart failure, systolic and diastolic. They have different 
mechanistic causes, but both lead to dyspnea or difficulty breathing.  In general, as the 
heart begins to fail by either systolic or diastolic mechanism, there is a backup of fluid in 
the pulmonary system that causes difficulty in breathing.  When heart failure occurs by 
diastolic mechanism, blood approaching from the pulmonary side of the circulation faces 
a higher than normal diastolic pressure in the left ventricle as its tissue is less compliant 
due to hypertrophy.  This decreased pressure difference between the two chambers 
creates a condition where blood has more difficulty passing from a higher-pressure 
system of the pulmonary system to a lower-pressure system of the ventricles.  The 
decreased passage from the pulmonary side to the left ventricle creates a backup of fluid 
into the pulmonary system, which leads to dyspnea (Carabello, 2013).   
In the case of systolic dysfunction, the hypertrophied ventricle may not be able to 
create a great enough pressure to maintain the baseline cardiac output or ejection fraction 
as the increase in wall thickness is not adequate to combat the rising pressure of the 
ventricle (Lester & Abbas, 2014).  As ejection fraction begins to fall, there is an increase 
in the preload of the cardiac ventricles, creating a condition where the atrium must 
generate higher pressures to move blood from the atrium to the ventricle.  This same 
situation of high ventricular pressure can be caused by direct lack of contractility due 
myocardial ischemic damage and therefore decreased ejection fraction.  In either case, 
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dyspnea is created due to the decreased movement of blood moving from the atrium to 
the ventricles causing pulmonary fluid back up (Carabello, 2013).    
As we have just seen, the symptomatic phase of aortic stenosis can include a 
variety of onset symptoms that lead to cardiac evaluation and diagnosis of aortic stenosis.  
Once evaluation for aortic stenosis has begun, the most accurate and best test for 
confirming aortic stenosis is a 2-dimensional Doppler echocardiography (Cary & Pearce, 
2013). Echocardiography is used to evaluate the rate and amount of fluid traveling 
through the aortic valve.  An increased rate of flow indicates stenosis or narrowing of the 
valve, as the same amount of fluid must travel through a smaller opening, leading to 
increased flow rate.  A great benefit of echocardiography is that is it inexpensive, 
noninvasive and widely available.  A major limitation in echocardiography comes with 
patients who have decreased left ventricular function that leads to underestimating the 
severity of the aortic stenosis.  As the left ventricle looses its power to pump the blood 
through the stenotic valve, the rate of flow will decrease even with the narrowed valve.  
The decreased flow rate will lead to the conclusion that there is less severe stenosis than 
is truly present.  As those with a weakened left ventricle and severe aortic stenosis are at 
an even higher risk for sudden death, such misinterpretation of the actual severity of 
aortic stenosis can have grave repercussions for surgical decision-making and patient 
health.  However, while these patients with weakened left ventricles and severe aortic 
stenosis need cardiac surgical intervention, they also carry a higher surgical risk (Rayner 
et al., 2014).   
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While echocardiography can test for blood flow, other tests are needed to evaluate 
cardiac function and assist in the diagnosis of calcific aortic valve disease.  Only a full 
picture of the state of a patient’s heart can provide the complete information needed to 
make appropriate decisions about the need for surgery and which type of surgery is best 
for that particular patient.   
Various tests are used to evaluate cardiac function.  Many of these tests help 
evaluate left ventricular hypertrophy, which is one of the greatest changes to the heart 
that has significant impact on cardiac function during aortic.  As the aortic stenosis 
becomes more severe, the left ventricle requires more force to create a great enough 
pressure to move the blood from the ventricle through the stenotic or narrowed valve in 
to the aorta and on to the systemic circulation.  Left ventricular hypertrophy begins when 
the cardiac tissue compensates to be able to provide increased force across the stenotic 
valve, which normally is capable of restoring baseline cardiac function.  The heart begins 
to fail as the hypertrophy becomes severe enough that the increased wall thickness of the 
cardiac tissue begins to cause detrimental effects on the amount of pressure the muscle is 
able to provide.  The wall thickness is inversely proportional to the amount of pressure 
that the ventricle can produce.  In the beginning, the increased amount of cardiac tissue 
allows the wall to increase contractive ability, but eventually the increased wall thickness 
is too detrimental and creates failure (Carabello, 2013; Dweck et al., 2012).   
The table below shows the different tests that are used to evaluate the cardiac 
function in assistance with the diagnosis of calcific aortic valve disease.  
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Table 1: Methods for diagnosing aortic stenosis- Each of the below studies are used to 
evaluate different aspects of associated symptoms, risk factors or clinical outcomes of 
aortic stenosis.  Taken from Cary & Pearce, 2013. 
 
 
 
 Another noninvasive test that is not listed in the above table that can be used to 
detect calcific aortic valve disease can be done in a routine physical utilizing cardiac 
auscultation.  Calcific aortic valve disease can be diagnosed by observation of a systolic 
ejection murmur.  The blood flowing through the narrowed stenotic valve causes an 
abnormal cardiac sound that is interpreted as a murmur (Rayner et al., 2014).   
In 1897, there was the first description of association of a systolic murmur with 
calcific aortic valve disease by Dr. W. Hoship Dickinson (Dickinson, 1897)He was able 
to use the findings of auscultation to indicate aortic stenosis prior to the advanced 
diagnostic tools that are available today.  He proved that the murmurs being heard by 
auscultation were not a mitral valve issue but truly an aortic valve issue.  During autopsy 
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of patients who had presented to medical care with a systolic murmur, he noted 
ventricular hypertrophy especially in the left ventricle.  He attributed the aortic valve 
blockage to rheumatic fever in one patient who had been infected when he was younger; 
in another patient, he attributed the stenosis to endocarditis.  The thoughts at the time 
were in accordance with the belief that aortic stenosis in those without rheumatic fever 
infection was caused by mechanism of endocarditis (Dickinson, 1897).   
 In addition to the variety of tests available to diagnose aortic stenosis, a system 
for grading the severity of the disease is also needed, as this defines the course of action 
for treatment.  This grading system is based on the jet velocity of the aorta, since it 
defines the severity of stenosis as blood travels from the left ventricle through the aortic 
valve to the aorta.  As the severity of disease increases, the area of the valve decreases, 
leading to an increased jet velocity.  The grade of aortic stenosis is mild, moderate, and 
severe with velocity at less than 3m/s, 3-4m/s, greater than 4m/s respectively.  The aortic 
stenosis in a patient is defined as severe when the aortic stenosis and obstruction is 
causing symptoms, such as syncope, angina, dyspnea or heart failure (Cary & Pearce, 
2013).   
Once aortic stenosis has been diagnosed, using the tests and grading systems 
described above, treatment options can vary, based on the severity and stage of the 
disease.  Treatments that have been tried to date include both pharmaceutical and surgical 
options. 
Initially, for those in the early stages of aortic stenosis, pharmaceutical 
intervention for treatment have been tried in order to avoid surgical intervention with its 
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concomitant higher risks.  Since many comorbidities exist with calcific aortic valve 
disease, such as atherosclerosis and high blood pressure, there has been a push to try to 
use the standard medications for these ailments in an attempt to slow the processes of 
calcification.  Statins have been used to slow calcification, angiotensin-converting 
enzymes used to combat heart failure with ventricular hypertrophy, and bisphosphonates 
used to reduce bone deposition on the aortic valve.  Unfortunately none of these drugs 
has provided a statistically significant effect on slowing the process of aortic stenosis 
(Salas et al.,  2012).  Without a reliable pharmaceutical intervention, there is a true need 
for surgical intervention to provide care.  
 
Figure 6: Pharmaceutical strategies for combating aortic stenosis-The above diagram 
displays the association of other medical diseases that are also linked with aortic stenosis.  
Each pharmaceutical intervention that is used to combat the baseline ailment has been 
attempted to slow the process of aortic stenosis.  Taken from Dweck et al., 2012 
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 There are currently three options of surgical intervention for those patients with 
calcific aortic valve disease that require surgery.  The first surgical intervention that is 
still the gold standard is AVR by open-heart surgery, the second developed surgery is 
balloon valvuloplasty and lastly, developed in 2002, is TAVR.  Surgical AVR and TAVR 
will be discussed specifically in the following work.  
 As described in an overview in the table below, each surgical technique has its 
own indication.  The indication for TAVR under current protocols only allows operating 
on those who are not surgical candidates for AVR and those at high-risk for AVR.  
Research is underway to determine if these protocols can be expanded.  Balloon 
valvuloplasty will not be greatly discussed here because it is solely used as a temporary 
device in order to sustain a patient until it is time for AVR or TAVR.  The procedure 
carries around a 10% mortality and or morbidity rate.  Overall balloon aortic 
valvuloplasty has the same long-term results for the patient as they would have obtained 
through the natural course of the disease, with a recurrence of symptoms in 80% of 
patients one-year post operation (Bohula et al.,  2013; Rayner et al., 2014).  
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Table 2: Options of surgery for aortic stenosis-The three surgical treatment options for 
aortic stenosis are AVR, TAVR or balloon aortic valvuloplasty.  Each surgical option has 
different indications for use.  Taken from Cary & Pearce, 2013. 
 
 
 
 The first surgical intervention to combat aortic valve disease came in 1952 when 
Dr. Charles Hufnagel of Georgetown University implanted the first mechanical valve in a 
patient, placed in the descending thoracic aorta to combat severe aortic regurgitation.  
This set the precedent for future developments that would allow cardiac surgical 
intervention to combat aortic stenosis.  The valve continued to function as the patient’s 
own valve would have, responding to pressure changes that caused the valve to open and 
close.  After insertion of the first valves, outcomes included patient improvement of 
congestive heart failure, cardiac remodeling to decrease hypertrophy, and improvement in 
exercise tolerance (Butany et al., 2002).   
 In 1960, Dr. Dwight Harken placed the first mechanical ball-valve prosthesis in 
the anatomical location of the natural aortic valve (Roberts, 1985).  This was the first 
intervention that could now provide assistance to those with aortic stenosis.  The 
placement of the valve in the anatomical position only became possible after the advent 
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of cardiopulmonary bypass used in surgical interventions.  Cardiopulmonary bypass 
allowed for surgeons to operate on any portion of the heart as the patients’ blood was 
oxygenated and pumped utilizing an external mechanical device.  At the time of the 
publication of the article in 1985, Dr. Harken’s second patient was still alive.  This 
indicated the promise of this then new intervention, since it showed, on only the second 
surgical attempt, an increase of at least 28 years in the patient’s life span with few 
complications (Roberts, 1985).   This promising start continued in the first 61 patients 
with AVRs at the National Institute of Health, who had a hospital mortality rate of 16% 
and a later mortality rate of 10%.  This was a significant improvement compared to the 
30-50% mortality rate one year after symptoms presented for those who did not receive 
surgery (Bajona et al., 2014; Ross & Braunwald, 1968).  
 Today for those undergoing AVR, the peri-operative mortality rate is 1-3% in 
those under 70 years old and 4-8% of those above 70 years of age (Rayner et al., 2014). 
This great improvement in the peri-operative patient outcome has led to adoption of AVR 
as the general practice for those with aortic stenosis.  The great patient outcome and 
improvement in post-operative health has led to an estimated 50,000 AVRs done in the 
United States per year (Bohula May & Faxon, 2013).  
 The establishment of a high quality surgical intervention has also led to 
standardizing the definition of who should be operated on and at what time during their 
clinical course.  The American College of Cardiology/American Heart Association was 
tasked with creating a system that would classify patients for both diagnostic and 
therapeutic interventions.  The classification system was based on who would benefit 
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from an intervention or diagnostic test.  Class I was defined by findings and/or opinion 
that a specific intervention would be beneficial to the patient.  Class II was for when there 
was differing evidence between if the intervention would be beneficial, IIa favoring the 
effectiveness and IIb when the usefulness is less clearly proven.  Class III was used when 
there was established evidence or opinion the intervention is not useful and at times can 
put the patient at risk for harm (Bonow et al., 1998).  
 While these standardized classifications helped when creating guidelines for 
surgical intervention, the definitive definition of when to operate with the scaling system 
becomes more difficult when comorbidities and age are considered as well.  Risk factors 
such as increased age or previous cardiac surgery, or comorbidities such as coronary 
artery disease, chronic lung disease, prior cerebrovascular accident, kidney failure, heart 
failure, or myocardial dysfunction increase the risk for those patients needing AVR 
(Bohula May & Faxon, 2013).  This increase in risk can place these patients in the class 
III category.  However, until 2011 with the advent of TAVR, there was no alternative to 
surgery for those in the class III category for AVR intervention.  With no treatment 
available, these patients unfortunately would routinely die within three to five years after 
their aortic stenosis became symptomatic (Cary & Pearce, 2013).  
 TAVR was the first development that could be used as a technique for long-term 
benefit to those who were not candidates for AVR.  Of the candidates requiring AVR, 
typically 30% of those with severe aortic stenosis would not undergo surgery due to 
comorbidities, left ventricular dysfunction or older age, but TAVR provided an option for 
these non-operable patients (Leon et al., 2010).  The surgery approved by the Food and 
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Drug Administration (FDA) in 2011 is still reserved for use only when surgical AVR is 
either contraindicated or a high-risk option for the patient due to comorbidities, age, or 
previous surgical status (Aksoy et al.,  2013).   
 TAVR is a procedure that is far less invasive than AVR as it does not require a 
median sternotomy or cardiopulmonary bypass.  As it does not require direct entry into 
the cardiothoracic cavity or placing the patient on an external device for blood 
oxygenation, the patient recovery time is improved and the patient is at less direct 
surgical risk.  The valve is implanted using minimally invasive techniques where the 
procedure can be done while the patient is under minimal anesthesia.  The TAVR is done 
through standard catheterization techniques with a device that has a biological heart valve 
attached to a stent that can be expanded in place.  The valve is guided from its entry 
location through the vasculature to the anatomical location where it is placed, expanding 
in order to displace the anatomical valve and assume its function.   
There are three different approaches to the implantation that can be utilized:  
transvenous, transseptal or retrograde.  Currently, the standard is the retrograde approach, 
where the device is placed retrograde starting at the femoral artery, guided by fluoroscope 
or echocardiography, and then positioned across the native aortic valve.   
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Figure 7: New surgical development-The placement of TAVR is depicted above with 
placement of the expanding valve across the anatomical aortic valve.  Aortic stenosis is 
also depicted showing the hardening of the leaflets and decreased opening for blood flow.  
Taken from Smith et al., 2011. 
 
The first device to be approved in the United States by the FDA was the Edwards 
SAPIEN valve, which consists of bovine pericardial tissue leaflets secured to a stainless 
steel frame stent that is expanded by use of balloon (Aksoy et al., 2013). The next valve, 
Medtronic CoreValve System, was approved for use in the United States on January 17, 
2014 (“Recently-Approved Devices > Medtronic CoreValve System - P130021,” 2014). 
.  
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A B 
Figure 8: Current valvular choices-The two above valves are those approved for use in 
the United States by the FDA.  A is the Edwards SAPIEN valve, B is Medtronic 
CoreValve.  Taken from Aksoy et al., 2013. 
 
The first case of use of TAVR was performed on a 52 year-old patient in 2002 
who was in need of a last-resort intervention to assist in his hemodynamic stability.  Post-
operatively at 48 hours he had decreased amounts of heart failure showing a great enough 
improvement that the patient was able to move from his bed.  Following the initial 
recovery from surgery he had multiple non-cardiac related issues, including pulmonary 
embolism, septicemia and right leg ischemia that eventually led to his decline and death 
17 weeks post-operation.  The researchers conducting the study noted that further 
improvements to the technology and the techniques surrounding TAVR are needed.  
Nonetheless, this technology had the possibility of providing relief to those who were 
otherwise non-surgical candidates (Cribier et al., 2002).   
While TAVR is still only approved for those that are in the high-risk category for 
AVR or those that have no surgical option, the fast progression of aortic stenosis once the 
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disease becomes symptomatic makes the approach a vital alternative surgery for those 
without AVR approval.  In addition, the increased prevalence of aortic stenosis and an 
aging population with a substantial subset of patients who are not good candidates for 
standard surgical procedures, a variety of interventions are needed to provide care for 
those affected and TAVR provides a possibility for treatment option.  As the utilization 
of TAVR continues there must be continued evaluation of the surgical outcomes in order 
to ensure the efficacy of the intervention compared to AVR. This study provides an 
evaluation of the current state of research that has been carried out on TAVR in order to 
evaluate the efficacy and safety of TAVR compared to AVR.  
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Specific Aims:  
 The interventions for aortic stenosis have seen many changes over the past twelve 
years with the advent of TAVR.  These changes have been particularly rapid in the 
United States over the past three years, following FDA approval for its use in the general 
population.  This thesis will look specifically at the two surgical techniques of AVR and 
TAVR to evaluate the patient outcome of the two procedures.  The data regarding 
patients operated on with TAVR who are at lower risk for AVR is not available due to 
the lack of current approval for this patient group.  The focus will be on patients who are 
at high risk for AVR and speculation of outcome for those that are lower risk for AVR.  
 The major risk that has been seen with TAVR over AVR is the risk of a 
cerebrovascular accident (stroke).  This specific patient risk will be evaluated here.  
Lastly, current research is being conducted to combat this risk of stroke, improving 
overall outcome and there will be evaluation of what changes must be taken in order to 
lower the associated risks in the patients who are in need of TAVR.  The thesis aims to 
show that TAVR will provide similar patient outcomes compared to those receiving AVR 
who are at high-risk for surgery, and provide insight to the future development of the 
newly developed technique.
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PUBLISHED STUDIES 
The first study carried out in the United States to evaluate the efficacy of TAVR 
on patients who were not candidates for surgical AVR was published in 2010 (Leon et 
al., 2010).  The study conducted by Leon et al. was used to compare the outcome of 
TAVR to standard therapy for those who were not surgical candidates of pharmaceutical 
and balloon aortic valvuloplasty intervention.  This trial was used to prove the safety and 
efficacy of TAVR over the current practice for this population.  This study improved on 
previous retrospective studies by prospectively evaluating 358 subjects who were 
randomly assigned to either a surgical intervention or to classical intervention (Leon et 
al., 2010).   During the surgical intervention, the Edwards SAPIEN bovine valve of 
Edwards Lifesciences, described earlier, was used.  The study was conducted from May 
11, 2007 to March 16, 2009 with patient evaluation and follow up at 30 days, 6 months 
and 1 year post operation (Leon et al., 2010).  In the Leon et al. study, of the 173 patients 
who received TAVR, 11 (6.4%) died within 30 days compared to 2.8% of those receiving 
standard therapy.  
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Table 3: Patient clinical results TAVR verses standard therapy-Outcome at day 30 
and 1 year post operation for TAVR verses classic treatment for those unable to undergo 
surgery.  
Transient ischemic accident (TIA) 
Transcatheter aortic valve implantation (TAVI).  
Not Available (NA) 
Taken from Leon et al., 2010.
 
 
As described earlier there was great concern about stroke risk for the patients who 
were assigned to the TAVR group.  At 30 days, TAVR verses standard therapy had a 
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stroke rate of 5.0% vs 1.1% respectively.  The stroke rate at one year was also elevated in 
the TAVR population at 7.8% verses in 3.9% in the standard therapy approach.  Analysis 
of outcome of those who survived surgery was much improved with TAVR compared to 
standard therapy.  At the benchmark of 1 year, 30.7% of the TAVR group and 50.7% of 
the standard therapy group were deceased.  Evaluation at one year showed that only 
42.0% of those with standard therapy were asymptomatic compared to 74.8% in those 
receiving TAVR (Leon et al., 2010).  
  
  
Figure 9: Cause of death curves and outcome period-The time from surgery to death is 
depicted for different causes of death.  Taken from Leon et al., 2010. 
 
 As shown above in the represented graphs, the survival rate was much improved 
with the use of TAVR over the use of standard therapy, reducing death from any cause, 
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cardiovascular death and rehospitalization.  The patients who did receive TAVR were at 
higher risk for surgical complications including stroke, vascular complications, and major 
bleeding which was seen in this population group as expected compared to the non-
surgical group.  For those who did survive the one-year follow up for both standard 
therapy and TAVR, the patients who received TAVR had greatly improved symptoms 
compared to standard therapy.  
 As part of the trial findings, the research team recognized some limitations to the 
new technology and surgical techniques.  These included flaws in the initial TAVR 
system.  These flaws included, requiring large femoral access, which likely led to 
vascular complications.  The research team also recognized that the higher risk for 
cerebral events for those undergoing TAVR could be attributed to the use of the large 
catheters and equipment used for the valve replacement (Leon et al., 2010).   
 This initial randomized trial provided the basis for establishing the benefits and 
safety of TAVR and led to a further study comparing the outcomes of high-risk patients 
undergoing TAVR verses AVR.  This surgical comparison study, published in 2011 by 
Dr. Smith et al., was conducted in conjuncture with the Leon, 2010 study.  The 699 
patients that were enrolled were high-risk patients originally screened for the Leon, 2010 
study but were found to be candidates for surgical intervention.  The 699 patients were 
randomly assigned to either undergo TAVR or surgical AVR and were followed up for 
their survival rate, post-operative complications and disease relief.  The study evaluated 
patient outcomes at 25 surgical centers, 22 located in United States, two in Canada and a 
single site in Germany.  The study defined patients to be at high risk for surgery if the 
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patients’ health status and comorbidities afforded a 15% chance of death within 30 days 
prior to surgery.   
 In this trial the patients that received a TAVR also had a Edwards SAPIEN valve 
implanted either by transfemoral or transapical approach (Smith et al., 2011). Although 
Edwards Lifesciences, the company that developed the valve, funded the study an 
independent statistics firm was utilized to analyze the data to ensure a lack of bias and 
confirm the accuracy of the results.  Those that were treated with AVR had an 8.0% death 
rate at 30 days post operation compared to 5.2% in those receiving TAVR.  The death 
rate at one year was 24.2% and 26.8% for TAVR compared with AVR respectively.  
There was a far higher rate of neurologic events in patients undergoing TAVR than AVR 
with 5.5% verses 2.4% at 30 days, and 8.3% verses 4.3% at 1-year post operation.  
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Table 4: Patient clinical results in TAVR vs. AVR- Outcome at day 30 and 1 year post 
operation for TAVR verses AVR.  Taken from Smith et al., 2011. 
 
 
 Evaluating other factors that did not include stroke or death found that TAVR and 
AVR had variable advantages and disadvantages for patient outcomes.  TAVR had a 
significant increased amount of vascular complication with 11.0% complication 
compared to 3.2% in AVR.  TAVR was better at avoiding major bleeding, 9.3% 
compared to 19.5% or new-onset atrial-fibrillation 8.6% compared to 16.0% in AVR.  
Evaluating recovery time and quality of symptom relief, at 30 days TAVR patients were 
able to walk further in a 6-minute walk test compared to the AVR group patients, and 
were out of the intensive care unit two days earlier than the AVR patients, who averaged 
	  39 
a five day stay and also had an overall average 8 day hospital stay compared to 12 in the 
AVR group.  The one-year evaluation showed similar clinical symptom outcome 
improvement between the two groups (Smith et al., 2011).  These findings of improved 
patient recovery time are of great advantage to the overall patient outcome as long 
hospital stays often lead to poorer long-term outcomes, given the risk of nonsurgical 
related infection, especially in the elderly population with weakened immune systems 
(Vincent et al., 2009).   
Another large difference in outcomes between the two surgical techniques was 
with moderate or severe paravalvular regurgitation.  This was present in 12.2% of TAVR 
patients compared to 0.9% in AVR patient at 30 days, and 6.8% in TAVR compared to 
1.9% in AVR patient group.  Aortic regurgitation is when the blood that was intended to 
go in a unidirectional flow, travels backward from the aorta to the ventricle.  Paravalvular 
regurgitation is when blood is able to flow around the implanted valve backwards from 
the aorta to the left ventricle, showing faults in the implanted valve as blood travels in a 
non-intended direction.  Although paravalvular regurgitation was a subsequent finding in 
the study, this study’s main goal was to prove that patients at high-risk for surgical 
complication had comparable survival one-year post operation using either AVR or 
TAVR (Munir & Schreiber, 2014; Smith et al., 2011). 
As mentioned above, the greatest concern for patient outcome in those receiving 
TAVR is risk of cerebrovascular accident or stroke.  Further evaluation is needed 
regarding this stroke risk, because the stroke rate for TAVR is significantly higher than 
for those operated on in AVR.  Analysis of these two risks must be considered while 
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comparing patient outcomes (Smith et al., 2011). A possible cause for this higher stroke 
rate could be due to the mechanics of the valve implant and the manipulation of calcified 
valve, which can create possible debris that can move to smaller vessels and cut off blood 
supply.  In a study of 50 subjects, the use of an examination device, Doppler, during 
surgical implantation showed that the most common cause of cerebral event occurred 
during surgically advancing the catheter internally over the aortic valve, balloon 
valvuloplasty, or during actual valve placement.  Doppler, which uses sound for 
examination, was utilized to evaluate for signals of ischemia or lack of blood supply 
during the seven portions of the surgical intervention that were most at risk for creating 
an embolus.  Lowered rates of stroke were the result of catheter advancement at the site 
of catheter entry point (Drews et al., 2011). These findings provide a target for improved 
treatment and insight into new technologies that could be developed and implemented to 
combat the current surgical stroke rate.  These will be discussed further in the next 
section.  
As the comparison of the two surgical techniques continues, there must be 
confirmation that the benefits of the new technology have long lasting positive outcomes.  
This evaluation must consider the extended benefit of TAVR beyond one-year post 
operation.  Consequently, Kodali et al. conducted a study in 2012 to evaluate patient 
outcomes between the two surgical techniques at two years post operation.  The patients 
that were evaluated in this study were the same 699 patients who received either TAVR 
or AVR in the Smith et al. 2011 trial.  In the patient group, 244 patients were treated with 
a transfemoral approach, 104 were treated using a transapical approach and 351 were 
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treated with surgical AVR.  In the time period between one year follow up and the second 
year, the TAVR group had 32 additional deaths compared to 25 additional deaths in the 
AVR group.  However, this difference in mortality between the two treatment approaches 
was not significant, with TAVR and AVR having a death rate of 33.9% and 35.9% 
respectively (Kodali et al., 2012a).  Both groups suffered four additional strokes, along 
with two transient ischemic attacks occurring in the transcatheter aortic valve 
implantation group and one in the AVR group between year one and year two follow up.  
This resulted with TAVR continuing to have a higher stroke rate at 11.2% compared to 
6.5% in AVR group (Kodali et al., 2012a).  
  
Figure 10: Comparing AVR to TAVR patient outcomes-The above graphs show the 
survival percentages as a function of time between those receiving TAVR and AVR.  
Taken from Kodali et al., 2012a. 
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Stroke as a cause of death was comparable in the two groups at two years with 
36.4% in the AVR group and 37.1% in the TAVR group.  Importantly for patient overall 
outcome, there were similar values of rehospitalization in the two groups over the two 
year follow up period, and also similar clinical outcome benefit between the two groups 
of those patients who survived.  Mortality is often associated with stroke, with 31% 
mortality in those that suffering a stroke in less than 24 hours after surgery and 14% 
mortality in those suffering a stroke past 24 hours after surgery compared to only a 4.6% 
mortality rate of those receiving AVR who did not suffer a stroke.  This same association 
was seen in the TAVR cohort where the 1-year mortality was 66.7% in those who did 
suffer a stroke compared to 27.7% in those who did not (Daneault et al., 2011; Kodali et 
al., 2012a).  
 In addition to risk of cerebrovascular accident causing death, aortic valve 
regurgitation with associated mortality was found to be elevated in the two year follow up 
of TAVR verses AVR.  Aortic regurgitation even when mild was associated with poor 
patient outcomes and death.  The aortic regurgitation that was observed was caused by 
valvular error from incomplete circumferential apposition of the valve insertion to the 
fibrous rings that surround the valvular opening.  This lack of apposition was found to be 
caused by the positioning of the valve, correct sizing of the valve, and specific calcific 
build up on the native valve that caused incomplete seal.  Without complete apposition to 
the walls of the opening, there is room for blood to leak backwards from the aorta to the 
left ventricle.  Moderate regurgitation was defined as 10% of blood flowing in the 
incorrect direction and was present in a low frequency during the two-year follow up 
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study.  The aortic regurgitation that was noted was stable between the year one and year 
two follow up without worsening of symptoms.  Approximately 40% of patients at the 
two-year evaluation had mild paravalvular regurgitation that puts them at a higher risk for 
death.  Those without any or with trace regurgitation had a much higher survival rate at 
the two-year follow up point (Kodali et al., 2012a).  
  
Figure 11:  The role of aortic regurgitation on patient mortality-The presence of 
aortic regurgitation had a higher association with mortality than those who did not suffer 
regurgitation.  Taken from Kodali et al., 2012b. 
   
In addition to stroke, another common neurovascular event that one is at risk for 
during surgery is cerebral ischemia or lack of blood supply to the brain, which is often 
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asymptomatic.  These events may not cause immediate cognitive decline, but over time 
can have very detrimental effects, including decrease in neurocognitive function and 
increased rates of dementia.  The Kodali et al. and Smith et al. trials only evaluated the 
post-operative death rate, and rate of cognitive decline strokes during the two surgeries.  
The trials did not evaluate potential longer-term negative impacts from cerebral ischemia 
with or without cognitive decline (Kodali et al., 2012b; Smith et al., 2011) 
A study published in 2010 by Kahlert et al. evaluated the incidence of clinical 
silent cerebral ischemia associated with TAVR (Kahlert et al., 2010).  During TAVR, 
patients are at higher risk for cerebral ischemia due to the risk of dislodging micro debris 
either during the catheter insertion or through direct manipulation of the calcified aortic 
valve.  This debris has the potential to cause embolic stroke, which in turn causes 
cerebral ischemia.   
The study compared the outcome of 32 patients undergoing TAVR to the outcome 
of 21 patients undergoing AVR.  Patients were analyzed for cognitive function prior to 
the procedure, immediately after anesthesia was completely reversed and at three months 
post operation.  Whole body magnetic resonance imaging was also used at each of these 
time intervals to evaluate the presence of any embolic lesion (Kahlert et al., 2010).  On 
neurologic evaluation, a fully reversible neurologic event that lasted less than 24 hours 
was considered a transient ischemic attack, while an event with neurologic deficit lasting 
over 24 hours was considered a stroke.  
Between the two subject groups no neurologic deficits were seen in the first 
evaluation of the patients post-operatively, but the AVR surgical group had one left-
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hemispheric stroke that presented in the second day post operation.  During post 
procedural imaging evaluation, the TAVR group had 84% of patients suffering new 
lesions with restricted diffusion compared to 48% in the AVR group.  The lesions that 
were present in the TAVR patient were consistent with embolic lesions.  An embolic 
lesion is caused by ischemia to a portion of tissue due to some type of embolus blocking 
blood flow to an area of tissue.  The embolus can be a blood clot, air bubble, atheroma, or 
other physical material such as calcified debris that moves through the circulation system 
with the potential to block blood flow, causing damage to any down stream tissue, with 
brain tissue being particularly susceptible to this risk.  Any damage to the brain also 
causes proportionately more potential negative impact to patient outcomes and quality of 
life.  However, in the three month evaluation there were no addition imaging findings in 
either group along with no neurological deficits recorded, and 80% of the foci detected 
postoperatively had resolved with no residual deficits found.  Besides the single stroke 
recorded in the AVR group, each patient had no change to their neurological outcome 
post operation (Kahlert et al., 2010).   
The researchers attributed the cause of the elevated level of lesions in the TAVR 
group to the higher level of atheromas or fat deposits on arterial walls in the patients who 
received this treatment.  These atheromas have the potential to dislodge and create an 
embolism.  With any cardiac intervention using catheterization there is risk for atheroma 
disturbance and subsequent embolism.  This embolism can occur even with the smallest 
size of catheters.  Those used during TAVR are significantly larger in size than most 
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catheters used due to the initially collapsed valve that must be guided into place (Kahlert 
et al., 2010).  
 In 2010, an additional study looked solely at stroke outcome in patients receiving 
TAVR.  The study enrolled 30 patients for evaluation of cerebral embolism and ischemia 
using magnetic resonance imaging; 22 were able to be fully evaluated according to the 
study protocol.  In those that were evaluated, 72.7% of patients developed new silent 
cerebral embolism, with only 3.6% of the patient population experiencing neurologic 
deficit three months post operation (Ghanem et al., 2010). This study had similar findings 
to the Kahlert 2010 study, which showed an elevated level of cerebral lesions detected 
with magnetic resonance imaging, but a similar low incidence of long-term neurologic 
deficits.  Continued evaluation of these patients is recommended in order to monitor the 
long-term effects that these silent cerebral lesions may have on patient outcomes.  Both 
studies confirmed that, in those patients who suffered new cerebral lesions, these lesions 
were caused by the mechanism of debris embolism.  This confirmation of embolism as 
the causal agent for these legions showed the importance of reducing embolus for this 
type of surgery.  New devices have been developed to focus on combating the risk of 
embolism and subsequent stroke for those undergoing TAVR (Ghanem et al., 2010). 
 As the thirty-day postoperative stroke rate during TAVR is still twice as high as 
undergoing AVR, prevention of stroke is a key priority in providing greater benefit to 
those undergoing TAVR.  One method that is being developed to assist in the prevention 
of stroke are devices that are implanted in the vasculature during surgery to deflect or 
capture embolus material in order to prevent cerebral ischemia and stroke.  The devices 
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are in the early stages of development and testing but have shown benefit during their use 
during surgery.  One device that was developed is the SMT Embolic Deflection Device, 
with publication of its first use in 2012.  The device was tested on 15 patients undergoing 
TAVR.  The device is placed at the aortic arch using catheterization and acts to deflect 
any microdebris that may be traveling in the vasculature toward the cerebral circulation.  
The device does not act to capture or remove the debris but deflects the emobli/debris to 
other portions of the circulation where they are less likely to cause harm (Onsea et al., 
2012). To test the effectiveness of the device, ten patients had baseline magnetic 
resonance imaging exams followed by one week follow up imaging after the surgical 
intervention.  During the follow-up imaging, there was an average of 3.2 new lesions in 
the patient group with device implementation compared to 7.2 new lesions from a 
previous similar trial without using the deflection device.  In follow up of the patients 
clinically, there was no development of new neurologic deficits in any patient besides one 
patient who had a transient ischemic attack two days post operation (Onsea et al., 2012).  
This study showed promise in the development and utilization of deflection devices in 
order to prevent strokes in those undergoing TAVR.  Larger clinical trials are needed in 
order to fully prove its efficacy.  Reducing the risk of stroke would provide a great 
improvement to the clinical outcomes of those patients undergoing TAVR.  
 Although there has been a large focus on clinical outcomes related to patient 
survival, in order to evaluate the full patient outcome, attention must also be placed upon 
the patient’s quality of life after TAVR and AVR.  While an operation may lengthen a 
patient’s life, it is important to determine if the operation also led to an improved quality 
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of life, not simply to survival.  The first study that was conducted to access this in the 
United States was done to evaluate quality of life improvements in those who underwent 
TAVR verses those non-surgical candidates who underwent standard treatment in the 
Leon study.  This prospective quality of life study evaluated 358 patients at baseline 
before surgery, at 1, 6, and 12 months post operation or post standard treatment 
(Reynolds et al., 2011).  The research team used two different evaluation scores to 
evaluate the patients:  the Kansas City Cardiomyopathy Questionnaire and the Medical 
Outcomes Study Short-Form Health Survey.  The Kansas City Cardiomyopathy 
Questionnaire focuses on heart failure, monitoring patient quality of life and symptoms 
due to this ailment on a scale of 0-100, with higher scores being more positive.  The 
Medical Outcomes Study Short-Form Health Survey was used to evaluate general health 
status of the patient on a scale of 0-50, also with the highest score being the most positive 
outcome.  The evaluations monitored improvement of patients’ quality of life and also the 
cardiac symptoms they were suffering from prior to the intervention.  The quality of life 
improvement is significantly higher in the patients that underwent TAVR verses standard 
therapy (Reynolds et al., 2011).  
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Table 5: Quality of Life Scales-The quality of life for patients undergoing TAVR verses 
AVR are compared in order to ensure the positive benefits of TAVR.  
KCCCQ (Kansas City Cardiomyopathy Questionnaire), SF-12 (Short-form 12 General 
Health Survey).  Taken from Reynolds et al., 2011. 
 
 
In each evaluation the mean difference from baseline was much more improved in 
the TAVR patient group than in the standard therapy group.  This initial evaluation 
showed the benefit of not only patient symptoms, but also the quality of life that the 
patient is afforded after TAVR verses standard therapy. 
 Another important study by Kala et al. in 2013 also compared quality of life the 
quality of life for those patients undergoing AVR verses TAVR (Kala et al., 2013).  The 
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study was an observational randomized study conducted at a single site and evaluated 
changes in the quality of life for 45 high-risk patients.  The patients were evaluated at 
baseline, day 30, day 90 and day 365 using a standardized EQ-5D three level 
questionnaire that evaluated quality of life.  At baseline there was no difference found in 
the quality of life between the two patient groups, and both groups reported similar health 
outcomes at day 30 and 90 (Kala et al., 2013).  At the one-year evaluation, while the 
group that underwent standard AVR experienced less anxiety/depression and displayed 
an upward trend in increase of general health, this upward trend was not found to be 
statistically significant.  For those who received TAVR surgery, however, their general 
health was significantly improved.  In fact, the greatest improvements in quality of life 
scores were seen in the transcatheter aortic valve implantation group, with improvements 
in physical functioning ability.  This study was able to prove with a small subset of 
patients that not only was TAVR comparable to AVR in patient symptomatic outcome, 
but that the quality of life for those receiving TAVR was improved over those receiving 
AVR (Kala et al., 2013). 
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DISCUSSION  
 
 As the medical field continues to advance and new technologies are implemented, 
each new technology must be assessed individually to ensure quality health outcomes for 
the patients involved.  Such quality is defined not only by patient survival, but also by 
relief of patient symptoms and improvement to their quality of life.  For many of the 
technologies being developed currently, there is already a known and effective 
intervention but the new technologies hope to build off of current practice to further 
improve the clinical outcome of the patients treated.  
This is the case with the development and practice of AVR and TAVR.  AVR has 
been an effective treatment for those suffering aortic stenosis that are capable of 
undergoing surgical intervention   TAVR was originally developed to assist those who 
were non-surgical candidates without recourse to treatment.  This new technology 
improved patient access to lifesaving treatment through a much less invasive procedure.  
With any new technology there are predicted risks and unforeseen complications that 
must be compared to the previous technique and those evaluations have been undertaken 
by the studies above.  
 The study done by Leon et al. 2010 was the first study conducted in the United 
States to evaluate the baseline safety of TAVR compared to standard therapy for patients 
who would not be candidates for AVR (Leon et al., 2010).  This was a pivotal study as it 
showed the first case where there was a surgical intervention option that had high success 
rates for those who were not candidates for AVR.  As mentioned above, without the 
reliable pharmaceutical intervention for those suffering aortic stenosis, this was the first 
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true treatment for the non-surgical candidate subgroup.  This study met its main goal of 
proving that the use of TAVR would afford a better outcome for those patients with 
aortic stenosis than the current pharmaceutical standard therapy approach for those who 
cannot undergo surgery.  The mortality rate at one and two-year follow up was much 
higher in the group that had standard therapy compared to TAVR.   
However, the researchers did find a higher rate of stroke in the TAVR patients.  
Smith et al. who compared the outcomes of high-risk patients undergoing TAVR vs. 
AVR found similar findings of elevated stroke rates in the TAVR group.  In both studies, 
the increased stroke rate was attributed to surgical complication due to either device 
technology or surgical technique.  The Smith trial proved that the outcome of TAVR vs. 
AVR was comparable when evaluating for mortality rate.  Although the stroke rate was 
elevated in the Leon and Smith studies, the new technology provided better or 
comparable outcomes for patients and the studies led to FDA approval for the use of 
TAVR on patients who were not candidates for surgical AVR, and approval for TAVR in 
high-risk patients respectively.  The two studies were well executed with a large sample 
size in both studies, using 21 and 25 different surgical sites in Leon and Smith trials, 
respectively, and using a randomized control for patient selection.  Utilizing different 
sites ensured that the safety of the device was not dependent on the surgeon, the hospital, 
or the assisting staff.  Patient randomization further ensured against potential operational 
biases that can occur, such as specific patient selection.  Although both studies were 
funded by Edwards Lifescience, the company who developed the device, there was a 
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separate co-principal investigator and an executive committee not associated with the 
companies that helped ensure the validity of the study (Leon et al., 2010). 
In order to fully evaluate the risk of stroke in patients undergoing TAVR and 
AVR, Kahlert et al. and Ghanem et al. used MRI evaluation to monitor for any sign of 
cerebral ischemia.  This type evaluation was not carried out in both the Smith and Leon 
studies.   
Cerebral ischemia is lack of blood flow to the brain; this can be symptomatic for a 
stroke or can be asymptomatic with no neurologic cognitive deficits.  The researchers 
hypothesized   that if there were elevated levels of strokes in TAVR patients there is 
likely elevated asymptomatic cerebral ischemia as well.  Although asymptomatic 
ischemia can pose no issue to the patient at the time of development, it has the potential 
to cause detrimental neurologic effects later on in the patients’ life.  Both Kahlert and 
Ghanem documented a significant increase in the incidence of cerebral ischemia in 
patients undergoing TAVR.  Further studies are needed to assess this increased level of 
cerebral ischemia in long-term patient evaluations to monitor its effect on cognitive 
decline.   
A limitation of both of these studies was the small sample size; the Kahlert study 
had 32 patients in their TAVR group and the Ghanem study, 30 patients.  Although these 
study samples were small, the findings were still significant in showing the increased 
incidence of cerebral ischemia, and demonstrated further need for its evaluation.  
Due to the high risk of stroke that has been documented in TAVR, there has been 
increased research to minimize this risk.  As one of the first steps in finding a solutions 
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for the increased rate of stoke in TAVR patients, Drew et al. utilized Doppler screening 
during surgery to find the cause of stroke.  The investigation was carried out as surgeries 
were being performed and the researchers found that there was an elevated risk of stroke 
due to microdebris being dislodged and becoming an embolus during surgery.  Patients 
were at highest risk during catheter advancement over the aortic valve, balloon 
valvuloplasty, or during the aortic valve expansion (Drews et al., 2011). 
In parallel with the findings of Drews that stroke was caused by embolisms often 
due to the surgical operation itself, devices have been developed to attempt to limit such 
embolus and concomitant cerebral ischemia.  Onsea et al. established a device that was 
capable of deflecting embolus away from cerebral circulation.  During the study, there 
was no neurologic deficit seen in any patient and there was a large decrease in the amount 
of cerebral ischemia found (Onsea et al., 2012).  The embolus deflection technology may 
provide key advancements in preventing the incidence of stroke, but the technology is 
still in its early development and must be further investigated.   
Another key aspect to limiting the rate of stroke in TAVR will be the 
development of surgical techniques and further technology advancement.  Kodali, Smith 
and Leon all attributed many of the risks with stroke to the large catheters that must be 
used for implantation of the prosthetic valve.  The design must continue to be evaluated 
to try to eliminate this size limitation that can lead to stroke in patients undergoing 
TAVR.  Regardless of the technology advancement, surgeon familiarity with the devices 
should provide improvement of the TAVR outcome overall, including stroke risk.  It was 
documented that it took 25 to 30 TAVR procedures to become proficient with the 
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techniques and with further experience there will hopefully be a decrease in surgical 
stroke complications (Alli et al., 2012). This must be evaluated later in time as many 
surgeons are still in early practice with the surgical technique. 
In addition to increased risk of stroke, Leon, Smith and Kodali all found increased 
risk of paravalvular regurgitation in those undergoing TAVR with associated increased 
mortality (Kodali et al., 2012b; Leon et al., 2010; Smith et al., 2011).  There needs to be 
development of surgical techniques, device improvements, or patient selection criteria to 
find ways to combat the increased rate of mortality.  This risk of paravalvular 
regurgitation was associated with valvular sizing issues and placement issues, both of 
which can hopefully be improved with the surgeon learning curve as mentioned above.  
As the findings of paravalvular regurgitation were associated with mortality, reduction in 
this surgical issue could provide great advancements for TAVR patient outcomes.  
The studies above were capable of comparing TAVR and AVR in short-term, 
thirty day, one and two year follow up, but the next challenge is comparing the surgical 
techniques on a long-term basis.  Although the overall mortality and symptom relief 
statistics for those undergoing TAVR are comparable to AVR at two years post operation 
as shown by Kodali et al., without further follow up there cannot be a full evaluation of 
the patient outcomes (Kodali et al., 2012b).  The long-term evaluations should monitor 
cardiac and neurologic effects of the device in order to ensure a comprehensive patient 
follow up of both survival and quality of life.  In the short term, thirty day and one year 
follow up, quality of life was proven by Reynolds to be higher in the TAVR patients.  
The increase in the asymptomatic cerebral ischemia is a major issue that needs to be 
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monitored to ensure that the patients do not have long-term neurologic effects due to 
TAVR that could highly affect their quality of life and change the findings of Reynolds.  
Lacking these long-term evaluations it is impossible to make a full comparison of patient 
outcomes between the two techniques.  
Another large issue with the field lacking these long-term studies is that there is 
no long-term follow up on the newly developed valves and evaluation of their device 
lifespan.  Biological valves have an increased risk of degeneration, with device failure 
presenting a large risk to patients, and this evaluation must be continued in order to 
compare the long-term patient outcome.  However, the risk of device failure when using 
TAVR is a greater risk to younger patients, who are less likely to undergo this surgery, 
than is the risk to older patients.  In older patients the device is implanted toward the end 
of life, and so the device will more likely remain functional for the remainder of patients 
lives.  The risk of device failure becomes significantly more important if TAVR is 
approved to be used on low-risk patients who tend to be younger and may have the 
device fail in their lifetime, requiring repeat surgery with its inherent risks (Bajona et al;., 
2014).  
The biggest limitation of all of the studies above in comparing the outcomes of 
those undergoing TAVR verses AVR is the patient groups that were utilized during the 
studies.  The studies were able to prove that patients undergoing TAVR who were not 
approved or at high-risk for AVR had comparable outcomes, but the studies lacked the 
ability to make conclusions on those at low-risk for surgical intervention.  This is 
compounded by the fact that the older patients who are normally at high-risk for AVR are 
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also at increased risk for stroke at baseline.  The findings of increased stroke rate in the 
studies are based upon a patient group that carry higher levels of comorbidities and a 
higher risk for stroke.  In order to make a better evaluation of the overall outcome of 
TAVR, studies of low-risk patients must be conducted.  The same investigators that 
conducted the Smith and Leon trials are now carrying out a trial to compare the outcome 
of AVR verses TAVR in intermediate-risk surgical patients.  This is the next large 
advancement that must be made in order to evaluate the outcomes of TAVR (“The 
PARTNER II Trial: Placement of AoRTic TraNscathetER Valves - Full Text View - 
ClinicalTrials.gov,” 2014).  
When looking at the two surgical techniques overall, both techniques have 
comparable overall survival in high-risk patients.  TAVR carries increased risk of stroke, 
asymptomatic cerebral ischemia, vascular injury and paravalvular regurgitation.  AVR 
has increased risk of bleeding, decreased improvement to the quality of life and increased 
hospital stay length with its attendant risks.  
With nearly twice the high risk of stroke for individuals undergoing TAVR verses 
AVR, it cannot definitively be stated that TAVR is a better option than AVR for all aortic 
stenosis patients despite comparable survival outcomes.  TAVR provides a drastic 
improvement in survival for patients that are unable to undergo surgery who would 
otherwise be limited to standard pharmaceutical therapy.  The benefit begins to blur as 
one debates AVR or TAVR for those at high risk for surgery, instead of those who are 
unable to undergo surgery.  Without long term follow up, the increased risk of stroke and 
comparable outcomes for TAVR must be considered on an individual patient case basis.   
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To further the science and improve patient treatment options and outcomes, more 
studies need to be conducted to look at TAVR compared to intermediate and low risk 
surgical patients.  Further study is also needed to create or strengthen surgical techniques 
and devices that lower the incidence of stroke.  Continuations of the surgical learning 
curve, decreased catheter size, and embolus blocking devices may provide significant 
improvements in lowering the stroke rate and increasing positive patient outcomes.  
There is currently not enough information to conclude that overall, for the population of 
patients with aortic stenosis, TAVR has similar outcomes as AVR.  AVR should continue 
to be the gold standard for those at low or intermediate surgical risk.  TAVR should 
continue to be used in patients that are not surgical candidates as proved by the extreme 
improvement of patient outcome.  Both techniques must be evaluated on a per patient 
basis when operating on those with high surgical risk as TAVR continues to carry a much 
larger stroke risk.  
The development of TAVR is a promising field, given its benefits as a less 
invasive surgery with decreased recovery time.  Further research is needed with a focus 
on long-term patient outcome as time passes.  Without these follow up studies, a 
comprehensive comparison of patient outcomes, from survival to quality of life, cannot 
be made.  As the science of TAVR continues to progress and subsequent strategies are 
developed, the options for those suffering from aortic stenosis will continue to increase, 
providing better outcomes for those affected.  
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